The Next Decade See Next-Generation HIV therapies Market Pushed Towards Exponential Advancement
Next-Generation HIV therapies Market is said to grow in the given forecast period. According to World health organization, in 2020, 37.7 million people in the world were infected with HIV. More that 73% of them had undergone ART treatment. 16% of all the population didn’t know that they were suffering from HIV.
This has led the market to take hike. Government has been initiating awareness amongst the people to have themselves tested, funding, pharmaceuticals industries be innovating drugs that no longer be resistant to the infected person. Technological advancements have been in demand. These are the factors that can augment the growth of the next generation HIV therapies market.
Adoption in advanced drug combinations by major players has been increased in the biotechnology and pharmaceuticals industries has caused a rapid growth in global HIV drug market. Bringing in new technologies and innovation leads to advancement in biological process.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32900
Government indulging themselves into spreading the word of awareness amongst the people has been the driving factor for the demand. Increase in the cases of HIV/ AIDS has again augmented the market growth.
The large patient pool has been demanding new long acting drugs with less frequency of consumptions have been driving the market. WHO reports increase in the HIV patient across different regions that leads to increase in the drug market.
According to CDC, in 2019, U.S. reported on an average of 1,189,700 million people of 13 years of age and above suffered from HIV infection. In addition, 13% of them was totally aware of the infection. U.S. has been the dominating region in leading chronic diseases count.
The rise in aging population has been demanding the new methodologies in the treatment of HIV infection. In 2020, ViiV Healthcare announced US FDA approval for its Rukobia (fostemsavir), 600 mg extended-release tablets. Merck Sharp & Dohme Corp, in 2019 got approved by US FDA for DELSTRIGO and PIFELTRO combination drugs. NIH is also funding the research institutes for the drug developments.
Europe, is the second largest region to boost the demand for the HIV Therapies market. The presence of many HIV Drug industries in this regions has made the market to grow at a significant rate. According to EU, HIV remains the most communicable disease in the Europe region.
Furthermore, the constant collaboration amongst each other has been driving the demand market. For instance, in 2020, Theratechnologies Europe Limited, collaborated with Loxxess for distribution of TROGARZO, an ART in Europe region.
The increase in disease prevalence has been demanding the HIV therapies market. The demand is significantly because of the rise of government funding, technological innovations, and well established healthcare infrastructure.
Global Next-Generation HIV Therapies Market: Key Players
- ViiV Healthcare
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Merck Sharp & Dohme Corp.
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Boehringer Ingelheim International GmbH
- AbbVie Inc.
- Genentech, Inc.
- Mylan N.V.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32900
Key Segments:
By Drug Type
- Integrase Inhibitors
- Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Combination HIV Medicines
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353